Managing Pediatric Fever

Required Documents

• Vital signs including temperature (rectal is gold standard for infants < 3 months)
• Physical examination with documentation of clinical appearance
• Prior fever workup results (if this is a follow-up)
• Immunization record

For infants < 3 months: ONLY rectal temperature is accepted. Axillary, tympanic, and temporal readings are unreliable in this age group. Rectal temperature ≥ 38.0°C (100.4°F) defines fever.

Step 1 — Age Stratification and Initial Approach

Age 0-28 Days (Neonate) — HIGH RISK

All febrile neonates require full evaluation and empiric antibiotics regardless of appearance.

Mandatory Workup

• CBC with differential
• Blood culture
• Urinalysis and urine culture (catheterized specimen)
• Lumbar puncture: CSF cell count, glucose, protein, Gram stain, culture
• CSF HSV PCR (if < 21 days, or if clinical concern for HSV at any neonatal age)
• Consider: CRP, procalcitonin, CSF enterovirus PCR (if season-appropriate)
• Chest X-ray if respiratory symptoms present

Empiric Treatment

• Ampicillin 75 mg/kg/dose IV Q8h (covers Listeria, GBS, enterococcus)
• Gentamicin 4-5 mg/kg/dose IV Q24h OR cefotaxime 50 mg/kg/dose IV Q8h (covers gram-negatives)
• ADD acyclovir 20 mg/kg/dose IV Q8h if: age < 21 days, vesicular lesions, seizures, CSF pleocytosis, elevated LFTs, maternal history of HSV, or ill appearance

Disposition

• Admit ALL febrile neonates ≤ 28 days to hospital pending culture results (minimum 36-48 hours)

Age 29-60 Days — AAP 2021 Clinical Practice Guideline

Risk Assessment Tools

The AAP 2021 guideline uses a stepwise approach based on inflammatory markers:

Step 1: Assess clinical appearance

• Ill-appearing → full workup + empiric antibiotics + admission (same as neonatal protocol)
• Well-appearing → proceed to laboratory risk stratification

Step 2: Laboratory evaluation (well-appearing 29-60 day infant)

• Urinalysis + urine culture (catheterized) — obtain on ALL
• Inflammatory markers: procalcitonin (PCT), CRP, ANC
  • PCT ≥ 0.5 ng/mL → higher SBI risk
  • ANC ≥ 4000/µL → higher SBI risk
  • CRP ≥ 20 mg/L → higher SBI risk

Step 3: Risk classification

AAP 2021 is specific to well-appearing, term, previously healthy infants 8-60 days. It does NOT apply to: preterm, immunocompromised, prior antibiotics, or ill-appearing infants.

Age 2-3 Months (61-90 Days) — Transitional

• Lower risk of meningitis than younger infants but still requires systematic evaluation
• UA and urine culture for all febrile infants in this age group
• Blood culture and CBC recommended
• LP: perform if ill-appearing, elevated inflammatory markers, or no clear viral source
• If well-appearing with clear viral source (e.g., bronchiolitis with positive RSV): may observe without LP or antibiotics with close follow-up

Age 3-36 Months — Post-PCV13/Hib Era

Risk of Occult Bacteremia

• In the post-conjugate vaccine era, risk of occult bacteremia in fully immunized, well-appearing children with fever is < 0.5%
• Focus shifts to identifying UTI (most common SBI in this age group) and focal bacterial infections

Workup Considerations

• UTI screening: catheterized UA + culture for: all females < 24 months with fever ≥ 39°C and no source; uncircumcised males < 12 months; circumcised males < 6 months
• Blood culture: not routinely needed for well-appearing, fully immunized children with focal viral illness
• Chest X-ray: if fever > 39°C + WBC > 20,000 with no source, or respiratory symptoms with high fever, or fever > 5 days
• High fever without source (≥ 39°C): CBC, blood culture, UA/UCx; consider CRP/PCT

Age > 36 Months — Older Children

• Focus on identifying the source clinically
• Workup guided by clinical findings rather than age-based protocols
• Fever > 5 days without source: evaluate for Kawasaki disease (IVIG criteria)
• Prolonged fever (> 10-14 days): consider FUO workup (CBC, CRP/ESR, blood cultures, ANA, LDH, uric acid, peripheral smear)

Step 2 — Fever Management (Symptomatic Treatment)

Antipyretics

Important Counseling Points

• Fever itself is not dangerous up to 40-41°C in immunocompetent children — it is a normal immune response
• Goal of antipyretics is comfort, NOT normalization of temperature
• Alternating acetaminophen and ibuprofen: AAP does not formally recommend this but acknowledges its common use; if done, careful dosing schedules to avoid confusion
• Do NOT use aspirin in children (Reye syndrome risk)
• Tepid sponge baths are not recommended (cause shivering, which raises core temperature)

Step 3 — Disposition and Follow-Up

Admission Criteria

• All febrile neonates ≤ 28 days
• Ill-appearing infants or children at any age
• Infants 29-60 days with positive UA or elevated inflammatory markers pending cultures
• Clinical suspicion for meningitis, bacteremia, or severe focal infection
• Inability to ensure reliable follow-up within 24 hours

Discharge Criteria (For Low-Risk Infants Sent Home)

• Well-appearing on reassessment
• Adequate oral intake
• Reliable caregiver with transportation
• Clear return precautions provided in writing
• Follow-up within 24 hours confirmed (appointment scheduled, not "call if worse")
• Pending culture results tracked by responsible provider

Return Precautions (Document These Were Given)

• Return immediately if: lethargy, inconsolable crying, poor feeding, bulging fontanelle, rash (petechial/purpuric), difficulty breathing, fever persists > 48-72 hours, or new symptoms develop

Checkpoint B — Fever Management Review

• Rectal temperature documented (for infants < 3 months)
• Age accurately determined and correct protocol applied
• Clinical appearance assessed and documented (well-appearing vs. ill-appearing)
• Appropriate workup obtained per age group (UA, CBC, blood culture, LP as indicated)
• Inflammatory markers (PCT, CRP, ANC) obtained and interpreted for 29-60 day group
• Empiric antibiotics administered when indicated (with correct dosing)
• HSV evaluation and acyclovir considered for neonates
• Disposition appropriate for risk level
• Return precautions provided and documented
• Follow-up within 24 hours arranged for discharged patients
• All [VERIFY] flags resolved or escalated

Quality Audit

Guidelines

• Follow AAP 2021 Clinical Practice Guideline: Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old
• Apply Rochester criteria, Philadelphia protocol, and Step-by-Step approach as historical context; AAP 2021 supersedes for 8-60 day group
• Follow NRP/neonatal guidelines for 0-7 day febrile infants (not covered by AAP 2021 guideline)
• Procalcitonin (PCT) is the most sensitive single inflammatory marker for SBI in young infants; prioritize its availability
• UTI is the most common SBI across all pediatric age groups — always consider
• Post-PCV13 era: occult bacteremia rate < 0.5% in fully immunized children — do not reflexively obtain blood cultures in well-appearing, immunized older infants
• Kawasaki disease: consider in any child with fever ≥ 5 days without clear source
• Rectal temperature is the only acceptable method for febrile infant evaluation under 3 months
• This skill produces clinical documentation; it does not replace clinical judgment